Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

被引：0
作者：
Nancy Devlin
Michael Herdman
Marco Pavesi
De Phung
Shevani Naidoo
Tomasz M. Beer
Bertrand Tombal
Yohann Loriot
Cristina Ivanescu
Teresa Parli
Mark Balk
Stefan Holmstrom
机构：
[1] Office of Health Economics,
[2] European Association for the Study of the Liver–Chronic Liver Failure (EASL-CLIF) Consortium,undefined
[3] Astellas Pharma Global Development,undefined
[4] Astellas Medical Affairs,undefined
[5] Global Health Economic Outcomes Research (HEOR),undefined
[6] OHSU Knight Cancer Institute,undefined
[7] Oregon Health & Science University,undefined
[8] Institut de Recherche Clinique (IREC),undefined
[9] Cliniques Universitaires Saint Luc,undefined
[10] Institut Gustave Roussy,undefined
[11] University of Paris Sud,undefined
[12] Quintiles,undefined
[13] Medivation,undefined
[14] Inc.,undefined
[15] Astellas Medical Affairs,undefined
[16] Global HEOR,undefined
来源：
Health and Quality of Life Outcomes | / 15卷
关键词：
Metastatic castration-resistant prostate cancer; Enzalutamide; Quality of life; Eq-5D;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 153 条
[81]  
Ivanescu C(undefined)undefined undefined undefined undefined-undefined
[82]  
Holmstrom S(undefined)undefined undefined undefined undefined-undefined
[83]  
Bui CN(undefined)undefined undefined undefined undefined-undefined
[84]  
Spalding J(undefined)undefined undefined undefined undefined-undefined
[85]  
Fizazi K(undefined)undefined undefined undefined undefined-undefined
[86]  
Basch E(undefined)undefined undefined undefined undefined-undefined
[87]  
Autio K(undefined)undefined undefined undefined undefined-undefined
[88]  
Ryan CJ(undefined)undefined undefined undefined undefined-undefined
[89]  
Mulders P(undefined)undefined undefined undefined undefined-undefined
[90]  
Shore N(undefined)undefined undefined undefined undefined-undefined
45678910111213